The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.
Guilhot
F
F
Département d'Hématologie et Oncologie Médicale, CHU La Milétrie, Poitiers, France.
Guerci
A
A
Fiere
D
D
Harousseau
J L
JL
Maloisel
F
F
Bouabdallah
R
R
Guyotat
D
D
Rochant
H
H
Najman
A
A
Nicolini
F
F
Colombat
P
P
Abgrall
J F
JF
Ifrah
N
N
Brière
J
J
Bauters
F
F
Navarro
M
M
Morice
P
P
Bordessoule
D
D
Vilque
J P
JP
Desablens
B
B
Tertian
G
G
Blanc
M
M
Chastang
C
C
Tanzer
J
J
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage*; D004361:Drug Tolerance; D005602:France; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000628:therapy*; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine; D006918:Hydroxyurea